- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | CEO von Apogee Therapeutics verkauft Aktien im Wert von 732.692 US-Dollar | 2 | Investing.com Deutsch | ||
| 16.12.24 | Apogee Therapeutics-Direktor Mark McKenna erwirbt Aktien im Wert von 990.775 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.12.24 | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | 76 | GlobeNewswire (Europe) | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| 10.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.12.24 | Apogee Therapeutics CEO Michael Henderson verkauft Aktien im Wert von 698.653 US-Dollar | 1 | Investing.com Deutsch | ||
| APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.12.24 | Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day | 6 | GlobeNewswire (USA) | ||
| 02.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.11.24 | Apogee Therapeutics Announces Agenda for Virtual R&D Day | 2 | GlobeNewswire (USA) | ||
| 25.11.24 | Apogee Therapeutics (NASDAQ:APGE) Now Covered by Analysts at Canaccord Genuity Group | 2 | MarketBeat | ||
| 18.11.24 | Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 | 1 | GlobeNewswire (USA) | ||
| 12.11.24 | Apogee Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 09.11.24 | Medizinischer Leiter von Apogee Therapeutics verkauft Aktien im Wert von 394.041 US-Dollar | 1 | Investing.com Deutsch | ||
| 24.10.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.10.24 | Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting | 3 | GlobeNewswire (USA) | ||
| 07.10.24 | Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now | 4 | Insider Monkey | ||
| 12.09.24 | Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit | 1 | GlobeNewswire (USA) | ||
| 09.09.24 | Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer | 141 | GlobeNewswire (Europe) | SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated... ► Artikel lesen | |
| 07.09.24 | Apogee Therapeutics CMO sells over $316k in company stock | 1 | Investing.com | ||
| 07.09.24 | Apogee Therapeutics CEO sells over $1.9 million in stock | 1 | Investing.com | ||
| 24.08.24 | Apogee therapeutics CFO sells shares worth over $289k | 1 | Investing.com |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,700 | +57,41 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,409 | +0,25 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,900 | +2,30 % | Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors | Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics
... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,750 | 0,00 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,580 | 0,00 % | Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts | More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,815 | -1,21 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 17,290 | 0,00 % | Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 8.6% - Here's Why | ||
| ASSERTIO | 0,800 | 0,00 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,530 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,510 | 0,00 % | Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why | ||
| SIGA TECHNOLOGIES | 6,050 | 0,00 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,200 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 5,485 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
| QUANTUM-SI | 1,930 | 0,00 % | Behind the Scenes of Quantum-Si's Latest Options Trends | ||
| TRAVERE THERAPEUTICS | 17,400 | -4,40 % | Travere Therapeutics, Inc. - 8-K, Current Report |
APOGEE THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 40,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APOGEE THERAPEUTICS INC finden Sie auf Wallstreet Online.
